Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment.

ABSTRACT:

Introduction

To quantify physicians' preferences for adjuvant renal cell carcinoma (RCC) treatments.

Materials and methods

A discrete-choice experiment was administered online to board-certified/eligible physicians. Physicians chose between pairs of hypothetical adjuvant therapies for a high-risk patient who had recently undergone a radical nephrectomy. Data were analyzed using random-parameters logit and latent-class models.

Results

Physicians (n = 250; 64% oncologists; 36% urologists) placed most importance on improvements in the chance of 5-year overall survival, followed by increased median disease-free survival and reduced risk of side effects. The analyses also highlighted their willingness to make tradeoffs between these benefits and risks. Physicians we

SUBMITTER: Vass C 

PROVIDER: S-EPMC11916416 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature